Relmada Therapeutics Ownership | Who Owns Relmada Therapeutics?

Overview ForecastFinancials Chart Transcripts

Relmada Therapeutics Ownership Summary

Relmada Therapeutics is owned by 41.02% institutional investors, 8.04% insiders, and 50.95% retail investors. Vanguard group is the largest institutional shareholder, holding 4.17% of RLMD shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.82% of its assets in Relmada Therapeutics shares.

RLMD Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Relmada Therapeutics	41.02%	8.04%	50.95%
Sector	Healthcare Stocks	49.73%	8.84%	41.43%
Industry	Biotech Stocks	47.04%	8.74%	44.21%
Idea	Psychedelic Stocks List	20.92%	14.49%	64.60%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	1.26M	4.17%	$3.77M
Deep track capital, lp	1.23M	4.10%	$3.70M
Vestal point capital, lp	1.20M	3.98%	$3.60M
Acadian asset management	1.19M	3.96%	$3.58M
Franklin resources	1.01M	3.36%	$3.04M
Parsons capital management inc/ri	975.95K	3.24%	$2.93M
Palo alto investors lp	732.40K	2.43%	$2.20M
Opaleye management	600.00K	1.99%	$1.80M
Blackrock	573.31K	1.90%	$1.72M
Jpmorgan chase	352.62K	1.17%	$1.06M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Opaleye management	600.00K	0.41%	$1.80M
Vestal point capital, lp	1.20M	0.27%	$3.60M
Palo alto investors lp	732.40K	0.25%	$2.20M
Parsons capital management inc/ri	975.95K	0.20%	$2.93M
Apricus wealth	78.86K	0.17%	$236.59K
Deep track capital, lp	1.23M	0.11%	$3.70M
Tang capital management	237.87K	0.07%	$713.62K
Advisorshares investments	90.03K	0.05%	$276.39K
Spotlight asset group	20.00K	0.04%	$60.00K
Pegasus asset management	26.96K	0.03%	$80.87K

Top Buyers

Holder	Shares	% Assets	Change
Franklin resources	1.01M	0.00%	382.41K
Tang capital management	237.87K	0.07%	237.49K
Jpmorgan chase	352.62K	0.00%	176.64K
Renaissance	88.78K	0.00%	53.77K
Advisorshares investments	90.03K	0.05%	19.98K

Top Sellers

Holder	Shares	% Assets	Change
Millennium management	64.36K	0.00%	-277.09K
Opaleye management	600.00K	0.41%	-159.00K
Goldman sachs group	-	-	-118.24K
Silverarc capital management	-	-	-99.38K
Morgan stanley	46.18K	-	-74.34K

New Positions

Holder	Shares	% Assets	Change	Value
Beacon pointe advisors	10.09K	0.00%	10.09K	$30.27K

Sold Out

Holder	Change
Blackston financial advisory group	-2.00
Innealta capital	-5.00
Smartleaf asset management	-35.00
Qube research	-56.00
Macquarie group	-856.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2024	76	-9.52%	12,376,687	-8.70%	41	2.03%	20	-4.76%	25	-21.88%
Jun 30, 2024	83	-15.31%	13,556,139	-5.26%	44	1.99%	21	-48.78%	31	24.00%
Mar 31, 2024	98	11.36%	14,308,498	5.06%	47	2.32%	41	2.50%	25	25.00%
Dec 31, 2023	88	-2.22%	13,619,817	-9.16%	45	1.82%	40	90.48%	20	-50.00%
Sep 30, 2023	90	-6.25%	14,992,668	-6.88%	49	1.74%	21	-51.16%	40	25.00%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	851.92K	2.82%	-
Franklin Biotechnology Discv A(acc)USD	845.70K	2.80%	-
Franklin Biotechnology Discovery A	456.40K	1.51%	-
Vanguard Institutional Extnd Mkt Idx Tr	353.63K	1.17%	-
Horizons Psychedelic Stock ETF	227.04K	0.75%	-36.13K
Fidelity Extended Market Index	161.21K	0.53%	15.95K
Bridgeway Ultra-Small Company	100.18K	0.33%	-14.70K
AdvisorShares Psychedelics ETF	93.08K	0.31%	-
Federated Hermes MDT Small Cap Growth IS	87.42K	0.29%	-8.59K
Federated Hermes MDT SCG Institutional	87.42K	0.29%	-8.59K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Sep 11, 2024	TRAVERSA SERGIO	Chief Executive Officer	Buy	$153.71K
Sep 09, 2024	TRAVERSA SERGIO	Chief Executive Officer	Buy	$150.62K
Sep 10, 2024	TRAVERSA SERGIO	Chief Executive Officer	Buy	$90.79K
Sep 09, 2024	CASAMENTO CHARLES J	-	Buy	$33.28K
Sep 11, 2024	Shenouda Maged	Chief Financial Officer	Buy	$71.15K

Insider Transactions Trends

Date	Buy	Sell
2024 Q4	-	-
2024 Q3	8	-
2024 Q2	-	-
2024 Q1	9	-
2023 Q4	-	-

RLMD Ownership FAQ

Who Owns Relmada Therapeutics?

Relmada Therapeutics shareholders are primarily institutional investors at 41.02%, followed by 8.04% insiders and 50.94% retail investors. The average institutional ownership in Relmada Therapeutics's industry, Biotech Stocks , is 47.04%, which Relmada Therapeutics falls below.

Who owns the most shares of Relmada Therapeutics?

Relmada Therapeutics’s largest shareholders are Vanguard group (1.26M shares, 4.17%), Deep track capital, lp (1.23M shares, 4.10%), and Vestal point capital, lp (1.2M shares, 3.98%). Together, they hold 12.25% of Relmada Therapeutics’s total shares outstanding.

Does Blackrock own Relmada Therapeutics?

Yes, BlackRock owns 1.90% of Relmada Therapeutics, totaling 573.31K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.72M$. In the last quarter, BlackRock decreased its holdings by -4.874K shares, a -0.84% change.

Who is Relmada Therapeutics’s biggest shareholder by percentage of total assets invested?

Opaleye management is Relmada Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.41% of its assets in 600K Relmada Therapeutics shares, valued at 1.8M$.

Who is the top mutual fund holder of Relmada Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Relmada Therapeutics shares, with 2.82% of its total shares outstanding invested in 851.92K Relmada Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools